Forecasted · Cooperative Agreement
Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)
National Institutes of Health, Department of Health and Human Services
Key facts
Copied from the official Grants.gov record. Last verified October 29, 2026.
- Program name
- Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional Drugs (RAPIDs)
- Issuing agency
- National Institutes of Health (Department of Health and Human Services)
- Opportunity number
- RFA-MH-27-150
- Funding type
- Cooperative Agreement
- Funding purpose
- Health
- Status
- Forecasted
- Application deadline
- Forecasted · estimated close November 13, 2026 (agency estimate)
- Agency estimates
- Estimated posting: October 10, 2026. Estimated award date: July 1, 2027. Estimates can change.
- Published award range
- Not published by the agency
- Estimated total program funding
- $20,000,000
- Expected number of awards
- 3
- Cost sharing or match required
- No
- Eligible applicants (official categories)
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see Additional Information on Eligibility)
- Relevant to
- Businesses and NonprofitsHow we determined this: Grants.gov eligibility includes small businesses or for-profit organizations. Grants.gov eligibility includes nonprofit organizations.
- Geographic restrictions
- None stated in structured data (federal opportunities are often nationwide). Check the eligibility details and full announcement for any limits.
- Assistance Listing (CFDA)
- 93.242
- Official source
- View on Grants.gov ↗
- Application URL
- www.grants.gov/search-results-detail/363875 ↗Apply through Grants.gov (Workspace) using the application package on the official listing, unless the full announcement names a different submission system.
- Source identifier
- Grants.gov opportunity ID 363875 · Funding opportunity number RFA-MH-27-150
- Posted
- September 16, 2026 · Source last updated September 16, 2026
- Last verified
- October 29, 2026 (against Grants.gov)
- Data completeness
- 92% of key fields published by the sourceNot published: published funding range.
- Record confidence
- mediumforecast — dates and amounts are agency estimates.
Eligibility details (from the agency)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
Description (from the official listing)
The National Institute of Mental Health (NIMH) intends to publish a Notice of Funding Opportunity (NOFO) to support the development of a research network to study rapid-acting psychotropic interventional drugs (RAPIDs), such as ketamine, esketamine, psilocybin, and other emerging treatments for serious mental illnesses. Preliminary studies suggest that RAPIDs can produce clinically meaningful improvements in mental health outcomes, in some cases following a single dose. However, important questions remain regarding their effectiveness, safety, durability of benefit, and implementation in routine clinical practice. As these interventions move toward broader use, rigorous real-world evidence is needed to identify how RAPIDs can be delivered safely, effectively, and sustainably across diverse patients, providers, and health care settings.The primary goal of this NOFO is to generate actionable evidence on the clinical effectiveness, safety, and implementation of RAPIDs. The resulting evidence from this study will help determine how RAPIDs can be safely and effectively integrated into clinical care and may inform future approaches to health care delivery.
Agency contact
Division of Services and Intervention Research
NIMHRAPIDS@nih.gov